



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

DIVISION OF
CORPORATION FINANCE

February 4, 2021

Lloyd Rowland
Sr. Vice President, General Counsel
151 Oyster Point Blvd.
Suite 400
South San Francisco
CA 94080

Re: CytomX Therapeutics, Inc.
Form 10-Q for the quarterly period ended September 30, 2020
Exhibit No. 10.3
Filed November 5, 2020
File No. 001-37587

Dear Mr. Rowland:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance